Biotech Acquisition Company in an S-4 filing outlined its proposed merger with Blade Therapeutics. The deal values the combined company at $352.8 million.
If approved, upon closing Blade Biotherapeutics is expected to list on the Nasdaq under BBTX. The deal was initially expected to close in the first quarter of 2022.
As announced in November, the transaction is expected to provide a pro forma cash balance of approximately $254.3 million before deducting estimated expenses of $25 million and including an approximately $24.3 million PIPE, as well as the $230 million in the SPAC’s trust, assuming no redemptions.
PIPE financing is anchored by Deerfield Management, Pfizer Ventures, Bristol Myers Squibb, MPM Capital and Osage University Partners.
Blade Therapeutics is focused on developing treatments for debilitating, incurable fibrotic and neurodegenerative diseases. Read more.
